Biozipcode
Biozipcode, Inc. is dedicated to developing a complete cure for diabetes and related diseases through innovative research and cell-targeting technology. The company collaborates with academic institutions and research organizations to advance regenerative medicine and pharmaceutical development, aiming to transform disease treatment from symptomatic management to complete cures.
Industries
Nr. of Employees
small (1-50)
Biozipcode
Seta Tsukiwa-cho, Otsu City, Shiga Prefecture, Biomedical Innovation Center, Shiga University of Medical Science, 520-2121
Products
Diabetes cure drug candidates (repurposed HDAC inhibitor + insulin approach)
Therapeutic candidates derived from repositioning of existing HDAC inhibitors, evaluated in preclinical models in combination with insulin to achieve diabetes remission.
Cell-targeted drug delivery platform (cell-targeting peptide system)
A platform of cell-targeting peptides (short amino-acid code sequences) designed to deliver therapeutics selectively to target cell types.
Companion diagnostic assay for diabetes-associated stem cells
Diagnostic product concept to detect abnormal hematopoietic/stem cells in peripheral blood as a biomarker for diabetes and patient stratification.
Tissue-regeneration materials
Materials under development intended to promote tissue repair (e.g., skin healing) with integration into host tissue without transplantation or sutures.
Diabetes cure drug candidates (repurposed HDAC inhibitor + insulin approach)
Therapeutic candidates derived from repositioning of existing HDAC inhibitors, evaluated in preclinical models in combination with insulin to achieve diabetes remission.
Cell-targeted drug delivery platform (cell-targeting peptide system)
A platform of cell-targeting peptides (short amino-acid code sequences) designed to deliver therapeutics selectively to target cell types.
Companion diagnostic assay for diabetes-associated stem cells
Diagnostic product concept to detect abnormal hematopoietic/stem cells in peripheral blood as a biomarker for diabetes and patient stratification.
Tissue-regeneration materials
Materials under development intended to promote tissue repair (e.g., skin healing) with integration into host tissue without transplantation or sutures.
Services
Consulting and advisory support for research, clinical trial planning, and regenerative medicine development.
Custom development of software systems and data-analysis workflows that leverage cell-targeting databases and bioinformatics pipelines.
Implementation support for overseas medical projects, including local clinical program integration and capacity-building (example: medical support project in Palau).
Contracted in vivo and in vitro research services including animal studies, translational assays, and preclinical evaluations.
Consulting and advisory support for research, clinical trial planning, and regenerative medicine development.
Custom development of software systems and data-analysis workflows that leverage cell-targeting databases and bioinformatics pipelines.
Implementation support for overseas medical projects, including local clinical program integration and capacity-building (example: medical support project in Palau).
Contracted in vivo and in vitro research services including animal studies, translational assays, and preclinical evaluations.
Expertise Areas
- Diabetes therapeutic development
- Cell-targeted drug delivery
- Drug repurposing and repositioning
- Preclinical and animal-model research
Key Technologies
- Cell-targeting peptides (short amino-acid code sequences)
- AI-driven targeting and database systems
- High-performance computing (GPGPU) for bioinformatics
- HDAC inhibitor–based therapeutics
News & Updates
The company announced an increase in capital to support ongoing research activities.
Details about the company's founding and research focus.
Participation in diplomatic activities related to international collaboration.
Publication of groundbreaking research demonstrating the potential to cure diabetes.
Updates on corporate governance and shareholder structure.
The company announced an increase in capital to support ongoing research activities.
Details about the company's founding and research focus.
Participation in diplomatic activities related to international collaboration.
Publication of groundbreaking research demonstrating the potential to cure diabetes.
Updates on corporate governance and shareholder structure.